---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件（201971016312913.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文乳酸林格注射液处方资料（仅供参考）

【英文名称】Lactated Ringers Injection

【适用证】

乳酸林格氏注射剂，USP被指示为水和电解质的来源或作为碱化剂。

【用法用量】

按照医生的指示。给药的剂量，速率和持续时间应个体化，并取决于使用指征，患者的年龄，体重，伴随治疗和患者的临床状况以及实验室测定。

VIAFLEX塑料容器中的所有注射均用于使用无菌和无热原设备进行静脉内给药。打开容器后，应立即使用内容物，不应存放以备后续输液。不要重新连接任何部分使用的容器。

当溶液和容器允许时，应在给药前肉眼检查肠外药物产品的颗粒物和变色。除非溶液清澈且密封完好，否则不要进行管理。

当添加乳酸林格氏注射剂USP时，必须使用无菌技术。添加添加剂后彻底混合溶液。不要存放含有添加剂的溶液。

添加剂可能与Lactated Ringer's Injection，USP不相容。与所有肠胃外溶液一样，添加剂与溶液的相容性必须在添加前通过检查可能的颜色变化和/或沉淀物，不溶性络合物或晶体的外观来评估。在添加物质或药物之前，确认它在水中是可溶的和/或稳定的，并且乳酸林格氏注射液，USP的pH范围是合适的。

必须参考添加药物的使用说明和其他相关文献。不应使用已知或确定为不相容的添加剂。

【禁忌】

对于其他含钙输液，同时给予头孢曲松和乳酸林格氏注射液，USP禁用于新生儿（≤28天龄），即使使用单独的输液管线（致命的头孢曲松钙盐沉淀风险） 新生儿的血液）。

对于超过28天的患者（包括成人），头孢曲松不得与静脉内含钙溶液同时给药，包括乳酸林格氏注射液，USP，通过相同的输液管线（例如，通过Y-连接器）。 如果使用相同的输注管线进行顺序给药，必须在用相容的液体输注之间彻底冲洗管线。

乳酸林格氏注射液，USP禁用于已知对乳酸钠过敏的患者。

【INDICATIONS AND USAGE】

Lactated Ringer’s Injection, USP is indicated as a source of water and electrolytes or as an alkalinizing agent.

【DOSAGE AND ADMINISTRATION】

As directed by a physician. Dosage, rate and duration of administration are to be individualized and dependent upon the indication for use, the patient’s age, weight, concomitant treatment and clinical condition of the patient as well as laboratory determinations.

All injections in VIAFLEX plastic containers are intended for intravenous administration using sterile and nonpyrogenic equipment. After opening the container, the contents should be used immediately and should not be stored for a subsequent infusion. Do not reconnect any partially used containers.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Do not administer unless the solution is clear and seal is intact.

When making additions to Lactated Ringer’s Injection, USP, aseptic technique must be used. Mix the solution thoroughly when additives have been introduced. Do not store solutions containing additives.

Additives may be incompatible with Lactated Ringer’s Injection, USP. As with all parenteral solutions, compatibility of the additives with the solution must be assessed before addition, by checking for a possible color change and/or the appearance of precipitates, insoluble complexes, or crystals. Before adding a substance or medication, verify that it is soluble and/or stable in water and that the pH range of Lactated Ringer’s Injection, USP is appropriate.

The instructions for use of the medication to be added and other relevant literature must be consulted. Additives known or determined to be incompatible should not be used.

【CONTRAINDICATIONS】

As for other calcium-containing infusion solutions, concomitant administration of ceftriaxone and Lactated Ringer’s Injection, USP is contraindicated in newborns (≤ 28 days of age), even if separate infusion lines are used (risk of fatal ceftriaxone calcium salt precipitation in the neonate’s bloodstream).

In patients older than 28 days (including adults), ceftriaxone must not be administered simultaneously with intravenous calcium-containing solutions, including Lactated Ringer’s Injection, USP, through the same infusion line (e.g., via Y-connector). If the same infusion line is used for sequential administration, the line must be thoroughly flushed between infusions with a compatible fluid.

Lactated Ringer’s Injection, USP is contraindicated in patients with a known hypersensitivity to sodium lactate.

---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件（201971016312913.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------